NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery

CompletedPhase 2

Sponsor: Pfizer

Conditions: Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement

Interventions: sitaxsentan (Thelin), sitaxsentan (Thelin), Placebo

Countries: United States

This is a multi-center, randomized study of sitaxsentan administered intravenously to subjects who are undergoing elective CABG, cardiac valve replacement, or combined CABG and cardiac valve replacement procedures that require CPB.

Eligibility overview

Sex: ALL

Age: 48 Years to 82 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Has been identified for coronary artery bypass grafting (CABG), aortic and/or mitral valve replacement, or combined CABG and cardiac valve replacement procedures that require cardiopulmonary bypass (CPB).

Exclusion Criteria:

* Requires an emergent or "emergency" CABG and/or cardiac valve replacement.

Locations (3)

Philadelphia, Pennsylvania, United States
Charleston, South Carolina, United States
Chattanooga, Tennessee, United States